Owkin believes that medical research should be collaborative, inclusive, and privacy-preserving. Today, Owkin is pioneering AI in healthcare. It leverages its collaborative federated learning software and expert AI capabilities to bring solutions to optimize drug development and improve patient care in oncology. Owkin’s work has been published in Nature Medicine and other top-tier journals. Owkin has raised over $70M from leading VC funds and is now working with the most prominent cancer centers and pharmaceutical companies in Europe and the US. Additionally, Owkin leads several federated learning consortia, including; MELLODDY, to facilitate 'co-opetive' drug discovery between pharma companies, and Healthchain, to allow collaborative research across multiple hospitals. Owkin was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology, and by Gilles Wainrib, Ph.D., an academic pioneer in the field of Artificial Intelligence in biology.

Biotechnology

Owkin

Owkin's headquarters in New York, NY, United States

Thomas Clozel

Jean-Philippe Vert

Jean-Frédéric Petit-Nivard

Andrew Pierce

Gilles Wainrib

Antonia Trower

Anne-Charlotte Paut

Rodrigo Barnes

Ablan De La Sablière

Mariabrisa Olivares

Hubert Chaperon

Darius Meadon

Vassili Soumelis

Yedidia Levy-Zauberman

Senior Solutions Architect

Machine Learning Engineer

Data Portfolio Analyst

Nicole Junkermann

Alex Pasteur

Olivier Elemento

Jacky Abitbol

Bruno Raillard

Roger Stupp

Nicolas Girard

Jakob Nikolas Kather

Shahrokh Shariat

Laurent Higueret

Jean-Jacques Bienaimé

Fabrice André

Raphaël Rousseau

Miriam Merad

Jean-Yves Blay

Jerome Pesenti

Joseph Lehár

Director of Pathology, Diagnostics

Description

People (5)

Thomas Clozel

Anna Huyghues-Despointes

Olivier Elemento

Jerome Pesenti

Venkat Sethuraman

Jobs (1)

Director of Pathology, Diagnostics